{ "api_version": "1", "request": { "url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=Placebo+and+Paroxetine&page=3", "query": { "intervention": "Placebo and Paroxetine", "page": 3 }, "page_size": 10 }, "pagination": { "page": 3, "page_size": 10, "total_count": 50, "total_pages": 5, "next_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=Placebo+and+Paroxetine&page=4&page_size=10", "previous_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=Placebo+and+Paroxetine&page=2&page_size=10" }, "source": "remote", "last_synced_at": "2026-10-12T23:55:42.073Z", "attribution": "Data derived from public ClinicalTrials.gov records. The official record at https://clinicaltrials.gov/ remains the source of truth for current availability, contacts, and full study details.", "notes": [ "This endpoint exposes only public summary fields — no participant contact emails, phone numbers, or scraped investigator contact details.", "For contact information and full protocol detail, follow each trial's `official_url` to the ClinicalTrials.gov record.", "This API is a navigational aid. It does not provide medical advice, eligibility determinations, or compensation guarantees." ], "trials": [ { "nct_id": "NCT04965272", "title": "A Study To Assess Adverse Events and Change in Disease Activity With Oral Cariprazine When Added to Antidepressant Therapies (ADTs) Compared to Placebo in Adult Participants With Generalized Anxiety Disorder (GAD) Who Have Had an Inadequate Response to ADTs Alone", "overall_status": "WITHDRAWN", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Generalized Anxiety Disorder" ], "interventions": [ { "name": "Cariprazine 0.75 mg/day", "type": "DRUG" }, { "name": "Cariprazine 1.5 mg/day", "type": "DRUG" }, { "name": "Cariprazine 3.0 mg/day", "type": "DRUG" }, { "name": "Placebo", "type": "OTHER" } ], "intervention_types": [ "DRUG", "OTHER" ], "sponsor": "AbbVie", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": "65 Years", "sex": "ALL", "summary": "18 Years to 65 Years" }, "enrollment_count": 0, "start_date": "2021-08-18", "completion_date": "2021-08-24", "has_results": false, "last_update_posted_date": "2022-04-12", "last_synced_at": "2026-10-12T23:55:42.073Z", "location_count": 36, "location_summary": "Little Rock, Arkansas • Colton, California • Costa Mesa, California + 29 more", "locations": [ { "city": "Little Rock", "state": "Arkansas" }, { "city": "Colton", "state": "California" }, { "city": "Costa Mesa", "state": "California" }, { "city": "Culver City", "state": "California" }, { "city": "Encino", "state": "California" } ], "official_url": "https://clinicaltrials.gov/study/NCT04965272" }, { "nct_id": "NCT00715039", "title": "Clinical Study Assessing a New Scale to Measure Onset of Action in Generalized Anxiety Disorder", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "NA" ], "conditions": [ "Anxiety Disorders" ], "interventions": [ { "name": "lorazepam", "type": "DRUG" }, { "name": "placebo", "type": "DRUG" }, { "name": "paroxetine", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Pfizer", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": "65 Years", "sex": "ALL", "summary": "18 Years to 65 Years" }, "enrollment_count": 169, "start_date": "2003-10", "completion_date": "2004-05", "has_results": false, "last_update_posted_date": "2008-10-03", "last_synced_at": "2026-10-12T23:55:42.073Z", "location_count": 15, "location_summary": "Glendale, California • Northridge, California • Orange, California + 10 more", "locations": [ { "city": "Glendale", "state": "California" }, { "city": "Northridge", "state": "California" }, { "city": "Orange", "state": "California" }, { "city": "San Diego", "state": "California" }, { "city": "Sherman Oaks", "state": "California" } ], "official_url": "https://clinicaltrials.gov/study/NCT00715039" }, { "nct_id": "NCT00191022", "title": "Comparison of LY686017 With a Marketed Drug in the Treatment of Social Anxiety Disorder", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Social Phobia" ], "interventions": [ { "name": "LY686017", "type": "DRUG" }, { "name": "paroxetine", "type": "DRUG" }, { "name": "placebo", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Eli Lilly and Company", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": "65 Years", "sex": "ALL", "summary": "18 Years to 65 Years" }, "enrollment_count": 185, "start_date": "2004-12", "completion_date": "2007-01", "has_results": false, "last_update_posted_date": "2007-02-13", "last_synced_at": "2026-10-12T23:55:42.073Z", "location_count": 15, "location_summary": "Burbank, California • Newport Beach, California • Denver, Colorado + 12 more", "locations": [ { "city": "Burbank", "state": "California" }, { "city": "Newport Beach", "state": "California" }, { "city": "Denver", "state": "Colorado" }, { "city": "New Britain", "state": "Connecticut" }, { "city": "Gainesville", "state": "Florida" } ], "official_url": "https://clinicaltrials.gov/study/NCT00191022" }, { "nct_id": "NCT00901407", "title": "Lamotrigine Augmentation in Resistant Depression", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "NA" ], "conditions": [ "Unipolar Depression" ], "interventions": [ { "name": "lamotrigine", "type": "DRUG" }, { "name": "placebo", "type": "DRUG" }, { "name": "paroxetine", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Louisiana State University Health Sciences Center in New Orleans", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": "65 Years", "sex": "ALL", "summary": "18 Years to 65 Years" }, "enrollment_count": 138, "start_date": "2003-12", "completion_date": "2007-04", "has_results": false, "last_update_posted_date": "2009-05-13", "last_synced_at": "2026-10-12T23:55:42.073Z", "location_count": 1, "location_summary": "New Orleans, Louisiana", "locations": [ { "city": "New Orleans", "state": "Louisiana" } ], "official_url": "https://clinicaltrials.gov/study/NCT00901407" }, { "nct_id": "NCT00338962", "title": "Naltrexone & SSRI in Alcoholics With Depression/PTSD", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE3" ], "conditions": [ "Alcoholism", "Depression", "PTSD" ], "interventions": [ { "name": "paroxetine", "type": "DRUG" }, { "name": "desipramine", "type": "DRUG" }, { "name": "Naltrexone", "type": "DRUG" }, { "name": "Placebo", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Yale University", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "21 Years", "maximum_age": "75 Years", "sex": "ALL", "summary": "21 Years to 75 Years" }, "enrollment_count": 88, "start_date": "2001-10", "completion_date": "2015-07", "has_results": true, "last_update_posted_date": "2016-02-05", "last_synced_at": "2026-10-12T23:55:42.073Z", "location_count": 1, "location_summary": "West Haven, Connecticut", "locations": [ { "city": "West Haven", "state": "Connecticut" } ], "official_url": "https://clinicaltrials.gov/study/NCT00338962" }, { "nct_id": "NCT00610610", "title": "Paroxetine-CR (Paxil-CR) in the Treatment of Patients With Fibromyalgia Syndrome", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE4" ], "conditions": [ "Fibromyalgia Syndrome" ], "interventions": [ { "name": "Paroxetine CR", "type": "DRUG" }, { "name": "Placebo", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Duke University", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": "65 Years", "sex": "ALL", "summary": "18 Years to 65 Years" }, "enrollment_count": 120, "start_date": "2002-01", "completion_date": "2002-12", "has_results": false, "last_update_posted_date": "2013-06-20", "last_synced_at": "2026-10-12T23:55:42.073Z", "location_count": 2, "location_summary": "Durham, North Carolina • Philadelphia, Pennsylvania", "locations": [ { "city": "Durham", "state": "North Carolina" }, { "city": "Philadelphia", "state": "Pennsylvania" } ], "official_url": "https://clinicaltrials.gov/study/NCT00610610" }, { "nct_id": "NCT00292370", "title": "Quetiapine Augmentation for Treatment-resistant PTSD", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE4" ], "conditions": [ "Combat Disorders", "Stress Disorders, Post-Traumatic" ], "interventions": [ { "name": "Open Label (OL) Paroxetine", "type": "DRUG" }, { "name": "Placebo", "type": "DRUG" }, { "name": "Quetiapine", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "VA Office of Research and Development", "sponsor_class": "FED", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": "75 Years", "sex": "ALL", "summary": "18 Years to 75 Years" }, "enrollment_count": 124, "start_date": "2006-01", "completion_date": "2009-05", "has_results": true, "last_update_posted_date": "2019-10-16", "last_synced_at": "2026-10-12T23:55:42.073Z", "location_count": 3, "location_summary": "Birmingham, Alabama • Tuscaloosa, Alabama • Charleston, South Carolina", "locations": [ { "city": "Birmingham", "state": "Alabama" }, { "city": "Tuscaloosa", "state": "Alabama" }, { "city": "Charleston", "state": "South Carolina" } ], "official_url": "https://clinicaltrials.gov/study/NCT00292370" }, { "nct_id": "NCT01254305", "title": "Safety and Efficacy of Levomilnacipran ER (F2695 SR) in Adults With Fatigue Associated With Major Depressive Disorder", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Major Depressive Disorder" ], "interventions": [ { "name": "Levomilnacipran ER", "type": "DRUG" }, { "name": "Paroxetine, Sertraline, Citalopram or Fluoxetine.", "type": "DRUG" }, { "name": "Placebo", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Forest Laboratories", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": "65 Years", "sex": "ALL", "summary": "18 Years to 65 Years" }, "enrollment_count": 262, "start_date": "2011-04", "completion_date": "2012-07", "has_results": true, "last_update_posted_date": "2014-08-06", "last_synced_at": "2026-10-12T23:55:42.073Z", "location_count": 20, "location_summary": "Birmingham, Alabama • Little Rock, Arkansas • Cerritos, California + 17 more", "locations": [ { "city": "Birmingham", "state": "Alabama" }, { "city": "Little Rock", "state": "Arkansas" }, { "city": "Cerritos", "state": "California" }, { "city": "Fort Myers", "state": "Florida" }, { "city": "Jacksonville", "state": "Florida" } ], "official_url": "https://clinicaltrials.gov/study/NCT01254305" }, { "nct_id": "NCT00385307", "title": "Efficacy and Safety of SR58611A in Patients With Major Depressive Disorder (SIRIUS)", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE3" ], "conditions": [ "Major Depressive Disorder" ], "interventions": [ { "name": "amibegron (SR58611A)", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Sanofi", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": "65 Years", "sex": "ALL", "summary": "18 Years to 65 Years" }, "enrollment_count": 680, "start_date": "2006-09", "completion_date": "2007-11", "has_results": false, "last_update_posted_date": "2009-03-25", "last_synced_at": "2026-10-12T23:55:42.073Z", "location_count": 1, "location_summary": "Bridgewater, New Jersey", "locations": [ { "city": "Bridgewater", "state": "New Jersey" } ], "official_url": "https://clinicaltrials.gov/study/NCT00385307" }, { "nct_id": "NCT00463242", "title": "A Placebo- and Paroxetine-controlled Study of the Efficacy, Safety and Tolerability of Agomelatine (25 or 50 mg) in the Treatment of Major Depressive Disorder (MDD)", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE3" ], "conditions": [ "Major Depressive Disorder" ], "interventions": [ { "name": "Agomelatine", "type": "DRUG" }, { "name": "paroxetine", "type": "DRUG" }, { "name": "placebo", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Novartis", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": "70 Years", "sex": "ALL", "summary": "18 Years to 70 Years" }, "enrollment_count": 501, "start_date": "2007-03", "completion_date": null, "has_results": false, "last_update_posted_date": "2020-12-23", "last_synced_at": "2026-10-12T23:55:42.073Z", "location_count": 46, "location_summary": "Phoenix, Arizona • National City, California • Orange, California + 40 more", "locations": [ { "city": "Phoenix", "state": "Arizona" }, { "city": "National City", "state": "California" }, { "city": "Orange", "state": "California" }, { "city": "Pasadena", "state": "California" }, { "city": "Pico Rivera", "state": "California" } ], "official_url": "https://clinicaltrials.gov/study/NCT00463242" } ] }